BERLIN/FRANKFURT, July 28 (Reuters) - The following are some
of the factors that may move German stocks on Tuesday:
CORONAVIRUS
German biotech BioNTech BNTX.O and U.S. drugmaker Pfizer
PFE.N said they would begin a pivotal global study to evaluate
their lead COVID-19 vaccine candidate. urn:newsml:reuters.com:*:nL3N2EY4HS
Germany announced plans for free, mandatory coronavirus
tests for holidaymakers returning from high-risk countries in
order to slow the spread of infections as the holiday season
kicks into high gear. urn:newsml:reuters.com:*:nL5N2EY4VH
The number of confirmed coronavirus cases in Germany
increased by 633, data from the Robert Koch Institute (RKI) for
infectious diseases showed. The reported death toll rose by 4.
WIRECARD WDIG.DE
Visa and Mastercard fined Wirecard for dubious transactions,
The Wall Street Journal reported. urn:newsml:reuters.com:*:nFWN2EY1EA
VOLKSWAGEN VOWG_p.DE
U.S. buyers of polluting Volkswagen vehicles received more
than $9.8 billion in settlements, the Federal Trade Commission
said. urn:newsml:reuters.com:*:nL2N2EY1RY
SIEMENS SIEGn.DE
Alstom ALSO.PA is set to gain EU antitrust approval to buy
Bombardier's BBDb.TO rail business, people familiar with the
matter said. Last year, EU regulators blocked Alstom's attempt
to merge rail assets with Siemens after they refused to offer
more concessions. urn:newsml:reuters.com:*:nL5N2EY5UM
FUCHS PETROLUB FPEG_p.DE
The company said that earnings may drop around 25% this year
amid the coronavirus pandemic. urn:newsml:reuters.com:*:nASN0009UC
DELIVERY HERO DHER.DE
Q2 results due
WASHTEC WSUG.DE
H1 results due
ANNUAL GENERAL MEETINGS
BAYWA BYWGnx.DE - 0.95 eur/shr dividend proposed
WASHTEC WSUG.DE - no dividend proposed
OVERSEAS STOCK MARKETS
Dow Jones .DJI +0.4%, S&P 500 .SPX +0.7%, Nasdaq .IXIC
+1.7% at close. .N
Nikkei .N225 -0.1%, Shanghai stocks .SSEC +0.6%. .T
.SS
Time: 4:31 GMT
ECONOMY
No major German economic data scheduled.
DIARIES DE/DIARY
REUTERS TOP NEWS TOP/NEWS
(Reporting by Berlin, Frankfurt and Gdansk newsrooms)
((frankfurt.newsroom@thomsonreuters.com; +49 30 2888 5169))